Physician profile
Stephen P Johnson
NPI 1750395356
$2,638.91
in general payments reported to CMS, 2019-2025
26 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $402 · 2021: $936 · 2022: $500 · 2024: $62.76 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.63 | 2019-2025 | |
| Janssen Biotech, INC. | $473.92 | 2019-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $194.71 | 2019-2022 | |
| Madrigal Pharmaceuticals | $122.81 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $120.89 | 2019-2021 | |
| Boston Scientific Corporation | $75.27 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $65.48 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $62.76 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.98 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $58.77 | 2021-2022 | |
| Celgene Corporation | $57.28 | 2021-2022 | |
| Intuitive Surgical, INC. | $52.25 | 2021 | |
| Ferring Pharmaceuticals INC. | $50.68 | 2019-2021 | |
| Allergan, INC. | $39.07 | 2020 | |
| Pfizer INC. | $35.57 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $30.78 | 2021 | |
| Ucb, INC. | $30.72 | 2019 | |
| Qol Medical, LLC | $26.17 | 2020-2022 | |
| Concordia Pharmaceuticals INC. | $23.83 | 2019 | |
| Mauna Kea Technologies, INC. | $17.98 | 2019 | |
| Redhill Biopharma INC. | $17.68 | 2021 | |
| Ardelyx, INC. | $16.08 | 2022 | |
| Evoke Pharma, INC. | $15.85 | 2022 | |
| Axonics, INC. | $13.06 | 2022 | |
| Shire North American Group INC | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.